Advanced in Dentatorubral-Pallidoluysian Atrophy

Ning Wang

Fuzhou, CN 
Advanced in Dentatorubral-Pallidoluysian Atrophy
Fuzhou, CN 
OverviewLocationsClinical Research

Overview

Ning Wang practices in Fuzhou, China. Ms. Wang is rated as an Advanced expert by MediFind in the treatment of Dentatorubral-Pallidoluysian Atrophy. Her top areas of expertise are Spastic Paraplegia Type 5A, Striatonigral Degeneration Infantile, Spastic Paraplegia Type 7, Thrombectomy, and Thymectomy.

Her clinical research consists of co-authoring 259 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Dentatorubral-Pallidoluysian Atrophy.

Gender
Female

Locations

Fuzhou, China
Other Locations
366 Tai Hu Road, Taizhou, China
State Key Laboratory For Crop Stress Resistance And High Efficiency Production, Yangling, 712100, China
State Key Laboratory Of Molecular Engineering Of Polymers, Shanghai, 200438, China
Shenzhen, 518083, China
China
Suzhou, 215008, China
State Key Laboratory Of Crop Stress Biology For Arid Areas, Xianyang, 712100, China
Xi'an, 710061, China
Guangzhou, China
Xiamen, China
Jiangsu Province Key Laboratory For Inflammation And Molecular Drug Target, Nantong, 226001, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3

259 Total Publications

Microglial Lag3 Drives α-Synuclein-induced Neurotoxic Activated (A1) Astrocytes and Neurodegeneration.
Microglial Lag3 Drives α-Synuclein-induced Neurotoxic Activated (A1) Astrocytes and Neurodegeneration.
Journal: bioRxiv : the preprint server for biology
Published: January 16, 2026

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Wang's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 59 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile